Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology

3 years ago

MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies…

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

3 years ago

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate…

AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical

3 years ago

IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused…

Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

3 years ago

SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in…

Philips and TriHealth announce multi-year partnership at heart of new TriHealth Heart & Vascular Institute on the campus of Bethesda North Hospital

3 years ago

Cardiac interventional suite at TriHealth Heart & Vascular Institute on the campus at Bethesda North Exam room in the cardiac…

CytoRecovery Awarded National Science Foundation Phase II SBIR Research Grant

3 years ago

Provides funding of $952,000 to advance the Company’s revolutionary CytoR1 platform for the rapid sorting and recovery of live cells.BLACKSBURG, Va.,…

Segra International Analytical Testing License

3 years ago

VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Segra International Corp. (“Segra”), an agriculture technology company is pleased to…

Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease

3 years ago

China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpointWARREN, N.J., Feb. 09, 2023…

Assure Holdings Announces Cost Reduction Plan to Accelerate Path to Profitability

3 years ago

DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative…

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

3 years ago

Patient enrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical…